Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$57.05 +0.3%	$57.73	$42.52 ▼ $62.89	$116.66B	0.24	11.03 million shs	7.84 million shs
GRI GRI Bio	$2.25 -2.6%	$2.27	$1.97 ▼ $80.36	$3.98M	-1.17	48,846 shs	51,035 shs
HCM HUTCHMED	$10.96 +2.6%	$13.11	$10.40 ▼ $19.50	$1.91B	0.26	61,997 shs	31,365 shs
INDV Indivior	$38.48 +0.9%	$35.44	$13.45 ▼ $41.00	$4.69B	0.88	1.68 million shs	627,489 shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.15%	-0.33%	+1.14%	-3.34%	+13.80%
GRI GRI Bio	-2.60%	+12.50%	-0.44%	-11.42%	-93.91%
HCM HUTCHMED	+2.38%	+0.83%	-13.50%	-21.60%	-36.09%
INDV Indivior	+0.92%	+2.29%	+0.34%	+23.69%	+181.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$57.05 +0.3%	$57.73	$42.52 ▼ $62.89	$116.66B	0.24	11.03 million shs	7.84 million shs
GRI GRI Bio	$2.25 -2.6%	$2.27	$1.97 ▼ $80.36	$3.98M	-1.17	48,846 shs	51,035 shs
HCM HUTCHMED	$10.96 +2.6%	$13.11	$10.40 ▼ $19.50	$1.91B	0.26	61,997 shs	31,365 shs
INDV Indivior	$38.48 +0.9%	$35.44	$13.45 ▼ $41.00	$4.69B	0.88	1.68 million shs	627,489 shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.15%	-0.33%	+1.14%	-3.34%	+13.80%
GRI GRI Bio	-2.60%	+12.50%	-0.44%	-11.42%	-93.91%
HCM HUTCHMED	+2.38%	+0.83%	-13.50%	-21.60%	-36.09%
INDV Indivior	+0.92%	+2.29%	+0.34%	+23.69%	+181.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.37	Hold	$61.31	7.48% Upside
GRI GRI Bio	2.00	Hold	$32.00	1,322.22% Upside
HCM HUTCHMED	2.40	Hold	$16.80	53.28% Upside
INDV Indivior	3.00	Buy	$39.33	2.22% Upside

Current Analyst Ratings Breakdown

Latest BMY, INDV, HCM, and GRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/1/2026	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $32.00
5/28/2026	HCM HUTCHMED	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.60
5/28/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/6/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/1/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
5/1/2026	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
4/21/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
4/9/2026	BMY Bristol Myers Squibb	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$68.00 ➝ $67.00
4/8/2026	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$45.00 ➝ $54.00
4/8/2026	BMY Bristol Myers Squibb	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$72.00
3/23/2026	BMY Bristol Myers Squibb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.42	$8.15 per share	7.00	$9.09 per share	6.28
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A
HCM HUTCHMED	$548.51M	3.49	$2.77 per share	3.96	$7.17 per share	1.53
INDV Indivior	$1.24B	3.79	$2.74 per share	14.02	($0.78) per share	-49.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$3.56	16.02	9.43	0.16	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
GRI GRI Bio	-$11.96M	-$74.16	N/A	N/A	N/A	N/A	-199.52%	-143.23%	8/13/2026 (Estimated)
HCM HUTCHMED	$456.91M	N/A	N/A	22.37	N/A	N/A	N/A	N/A	8/3/2026 (Estimated)
INDV Indivior	$210M	$1.95	19.73	9.01	N/A	19.44%	-219.26%	29.40%	7/30/2026 (Estimated)

Latest BMY, INDV, HCM, and GRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q1 2026	GRI GRI Bio	-$1.6050	-$1.61	-$0.0050	-$1.61	N/A	N/A
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
4/30/2026	Q1 2026	INDV Indivior	$0.64	$0.96	+$0.32	$3.45	$272.84 million	$317.00 million
3/31/2026	Q1 2026	INDV Indivior	N/A	$0.96	N/A	$3.45	N/A	$317.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	4.42%	+1.61%	70.79%	17 Years
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.10	1.42	1.28
GRI GRI Bio	N/A	14.20	14.21
HCM HUTCHMED	0.05	4.96	4.83
INDV Indivior	N/A	0.86	0.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GRI GRI Bio	33.95%
HCM HUTCHMED	8.82%
INDV Indivior	60.33%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
GRI GRI Bio	8.73%
HCM HUTCHMED	3.60%
INDV Indivior	0.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
GRI GRI Bio	1	1.77 million	1.62 million	Not Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
INDV Indivior	1,051	121.92 million	121.02 million	Not Optionable

BMY, INDV, HCM, and GRI Headlines

Recent News About These Companies

Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?

2 hours ago | insidermonkey.com

Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why

June 12 at 3:00 PM | msn.com

INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026

June 12 at 11:22 AM | zacks.com

Is Indivior Stock a Buy After Higher 2026 Guidance?

June 12 at 11:16 AM | zacks.com

INDV Stock: What Sublocade Growth Signals for 2026

June 12 at 11:16 AM | zacks.com

Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Buy" from Brokerages

June 12 at 5:05 AM | americanbankingnews.com

Ryan Preblick Sells 36,000 Shares of Indivior (NASDAQ:INDV) Stock

June 12 at 4:29 AM | americanbankingnews.com

Indivior (NASDAQ:INDV) CFO Sells $1,357,200.00 in Stock

June 11 at 7:23 AM | insidertrades.com

Indivior: A Stronger Business Than When I First Covered It

June 9, 2026 | seekingalpha.com

5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics

June 2, 2026 | zacks.com

What to Know About This Fund's $74.8 Million Indivior Sale

May 30, 2026 | finance.yahoo.com

Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%

May 30, 2026 | aol.comA

Indivior Pharmaceuticals Inc.

May 24, 2026 | money.usnews.com

Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect?

May 21, 2026 | msn.com

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

May 20, 2026 | globenewswire.com

The Bull Case For Indivior Pharmaceuticals (INDV) Could Change Following Upgraded Outlook And $175M Buyback - Learn Why

May 20, 2026 | finance.yahoo.com

Indivior Pharmaceuticals Inc. (INDV) Is a Great Choice for 'Trend' Investors, Here's Why

May 18, 2026 | zacks.com

Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now

May 14, 2026 | zacks.com

Indivior to Participate in Upcoming Investor Conferences

May 14, 2026 | globenewswire.com

A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Strong Recent Share Price Run

May 11, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, INDV, HCM, and GRI Company Descriptions

Bristol Myers Squibb NYSE:BMY

$57.05 +0.15 (+0.26%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$57.15 +0.10 (+0.18%)

As of 06/12/2026 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GRI Bio NASDAQ:GRI

$2.25 -0.06 (-2.60%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$2.25 +0.00 (+0.04%)

As of 06/12/2026 07:56 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

HUTCHMED NASDAQ:HCM

$10.96 +0.28 (+2.62%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$10.96 0.00 (0.00%)

As of 06/12/2026 04:11 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Indivior NASDAQ:INDV

$38.48 +0.35 (+0.92%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$39.00 +0.52 (+1.35%)

As of 06/12/2026 07:46 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, INDV, HCM, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, INDV, HCM, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, INDV, HCM, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, INDV, HCM, and GRI Company Descriptions

Bristol Myers Squibb NYSE:BMY

GRI Bio NASDAQ:GRI

HUTCHMED NASDAQ:HCM

Indivior NASDAQ:INDV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, INDV, HCM, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, INDV, HCM, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, INDV, HCM, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, INDV, HCM, and GRI Company Descriptions

Bristol Myers Squibb NYSE:BMY

GRI Bio NASDAQ:GRI

HUTCHMED NASDAQ:HCM

Indivior NASDAQ:INDV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools